The Cooper Companies, Inc. reported a solid financial performance for the fiscal year ending October 31, 2025, with net sales reaching $4.09 billion, a 5% increase from $3.90 billion in the previous year. The company's gross profit also rose to $2.68 billion, up from $2.60 billion, although the gross margin slightly decreased to 66% from 67% due to inventory write-offs and severance costs related to workforce optimization initiatives. Operating income was reported at $682.9 million, a decrease from $705.7 million in fiscal 2024, primarily attributed to increased operating expenses.
CooperVision, one of the company's two business segments, saw net sales of $2.74 billion, a 5% increase from the previous year, driven by strong demand for its silicone hydrogel contact lenses, particularly the Biofinity and MyDay brands. The segment's growth was bolstered by favorable foreign exchange rate fluctuations, contributing approximately $16 million to sales. In contrast, CooperSurgical's net sales increased by 5% to $1.35 billion, with growth in both office/surgical and fertility product categories, aided by the acquisition of obp Surgical in August 2024.
The company has made strategic moves to enhance its market position, including the acquisition of Cook Medical assets for $300 million, which is expected to strengthen its offerings in obstetrics and gynecology. Additionally, CooperVision received regulatory approvals for its MiSight 1 day lens in China and Japan, further expanding its product portfolio in myopia management. As of October 31, 2025, Cooper Companies employed over 15,000 people globally, with a focus on fostering a diverse and inclusive workplace.
Looking ahead, Cooper Companies remains optimistic about the long-term growth prospects in the contact lens and healthcare markets, despite facing challenges such as inflation, supply chain disruptions, and geopolitical uncertainties. The company plans to continue investing in product development and geographic expansion to capture market share, particularly in emerging markets. The management's outlook reflects a commitment to navigating these challenges while pursuing growth opportunities in both CooperVision and CooperSurgical segments.
About COOPER COMPANIES, INC.
The Cooper Companies is a global medical device firm specializing in vision correction and women’s health. Its segments, CooperVision and CooperSurgical, develop contact lenses, fertility products, and surgical devices. Serving healthcare providers and patients worldwide, the company emphasizes innovation, quality, and strategic acquisitions to improve clinical outcomes and expand market share in ophthalmology, reproductive health, and related fields.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.